James M. Murithi - Concepedia

Author

James M. Murithi

Columbia University Irving Medical Center ORCID

Also Known As

James M. Murithi, Murithi, James, Murithi, James Muriungi

Publications

884

Citations

H-Index

Concepts

All Affiliations

Columbia University Irving Medical Center University of California San Diego University of Cape Town Massachusetts Institute of Technology Pennsylvania State University

About

James M. Murithi is an author at Columbia University Irving Medical Center specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	129
2	Natural Sciences	1	1	80
3	Biochemistry	1	1	80
4	Immunology	1	1	80
5	Molecular Biology	1	1	80

James M. Murithi

Publications

881

Citations

H-Index

Page 1

	Year	Citations
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics Annie N. Cowell, Eva S. Istvan, Amanda K. Lukens, Science	2018	269
Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity Manu Vanaerschot, James M. Murithi, Charisse Flerida A. Pasaje, Cell chemical biology	2020	90
Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery James M. Murithi, Edward Owen, Eva S. Istvan, Cell chemical biology	2019	88
Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents Barbara H. Stokes, Euna Yoo, James M. Murithi, PLoS Pathogens Antiparasitic AgentMalariaImmunologyMolecular BiologyDrug Resistance	2019	80
Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention Robert L. Summers, Charisse Flerida A. Pasaje, João Pedro Pisco, Cell chemical biology	2021	76
A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin Deyun Qiu, Jinxin V. Pei, James E. O. Rosling, Nature Communications	2022	53
Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity Manu Vanaerschot, Leonardo Lucantoni, Tao Li, Nature Microbiology Antimalarial CandidatesAntiparasitic AgentMedicineMalariaPharmacotherapy	2017	49
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance James M. Murithi, Cécile Pascal, Jade Bath, Science Translational Medicine	2021	49
Dioxins and related environmental contaminants increase TDP-43 levels Peter E.A. Ash, Elizabeth A. Stanford, Ali Al Abdulatif, Molecular Neurodegeneration	2017	46
The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple <i>Plasmodium</i> kinases and life cycle stages Lauren B. Arendse, James M. Murithi, Tarrick Qahash, Science Translational Medicine	2022	42

Page 1